Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in High-risk Smoldering Multiple Myeloma
NCT06183489Phase 2Active, not recruiting
- Start
- May 2024
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of elranatamab in smoldering multiple myeloma (SMM). Started May 2024; status: active, not recruiting.
02
Drugs
elranatamab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT06183489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06183489.